Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
暂无分享,去创建一个
J. Leonard | S. de Vos | R. Fisher | A. Krishnan | S. Lonial | B. Djulbegovic | A. Boral | O. O’Connor | A. Goy | M. Robertson | S. Bernstein | E. Stadtmauer | B. Kahl | H. Shi | E. Epner | Hongliang Shi
[1] D. Esseltine,et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] V. Diehl,et al. Recommendations for revised response criteria for malignant lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Chott,et al. Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Pham,et al. Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas , 2006 .
[5] T. Lister,et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Siebert,et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. , 2006, Blood.
[7] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[8] F. Cavalli,et al. Update on the molecular biology of mantle cell lymphoma , 2006, Hematological oncology.
[9] L. Staudt,et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. Chella,et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Peschel,et al. Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach , 2006, Leukemia & lymphoma.
[12] M. Gordon. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .
[13] M. Taniwaki,et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] L. Pham,et al. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. , 2006, Blood.
[15] E. Campo,et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.
[16] D. Esseltine,et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. , 2005, Blood.
[17] H. Goldschmidt,et al. Hematologic Profiles in the Phase 3 APEX Trial. , 2005 .
[18] W. Hiddemann,et al. Inhibition of Proteasome Is Associated with Early Alterations of Cell Cycle Regulators and Induces Synergistic Antitumour Activities in Mantle Cell Lymphoma in a Sequence Dependent Manner. , 2005 .
[19] A. Rosenwald,et al. Altered Cellular Protein Levels of Tumor Suppressor Genes and Heat Shock Elements (TRAP1) Indicate Sensitivity to the Proteasome Inhibitor Bortezomib (Velcade®) in Mantle Cell Lymphoma. , 2005 .
[20] G. Marti,et al. Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma. , 2005 .
[21] J. Vose,et al. Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results. , 2005 .
[22] Michael L. Wang,et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Witzig. Current treatment approaches for mantle-cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Michael E. Williams,et al. Biology and therapy of mantle cell lymphoma , 2005, Current opinion in oncology.
[25] R. Fonseca,et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Richard Rosenquist,et al. Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. , 2005, Blood.
[27] A. Hagemeijer,et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma , 2005, British journal of haematology.
[28] E. Hoster,et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Ferlay,et al. Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] M. Ghielmini,et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Zelenetz,et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Michael L. Wang,et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Fisher. Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] P. Richardson,et al. Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Peter Boyle,et al. Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.
[36] P. Moreau,et al. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. , 2005, Haematologica.
[37] R. Gascoyne,et al. Phase II Trial of Bortezomib in Mantle Cell Lymphoma. , 2004 .
[38] D. Esseltine,et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma , 2004, British journal of haematology.
[39] J. Adams. The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.
[40] W. Hiddemann,et al. Mantle cell lymphoma: established therapeutic options and future directions , 2004, Annals of Hematology.
[41] E. Dees,et al. The proteasome as a target for cancer therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] P. Mclaughlin,et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] L. Pham,et al. Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis1 , 2003, The Journal of Immunology.
[44] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[45] R. Gascoyne,et al. Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy , 2003 .
[46] R. Gascoyne,et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Beverly S Mitchell,et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] J. Gribben,et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Leonard,et al. Biology and management of mantle cell lymphoma , 2001, Current opinion in oncology.
[50] C. Crews,et al. The ubiquitin‐proteasome pathway and proteasome inhibitors , 2001, Medicinal research reviews.
[51] G. Salles,et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low‐grade non‐Hodgkin's lymphoma , 2001, British journal of haematology.
[52] M Chilosi,et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.
[53] B. Coiffier,et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] H. Kantarjian,et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] V. Diehl,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.
[57] M. Tiemann,et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] J. Bosq,et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] R. Gascoyne,et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. , 1997, Blood.
[60] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[61] B. Nathwani,et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. , 1995, Blood.
[62] F W MULSOW,et al. Cancer incidence and mortality , 2019, Health at a Glance: Europe.